ANIX Stock Overview A biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Anixa Biosciences, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Anixa Biosciences Historical stock prices Current Share Price US$2.92 52 Week High US$4.79 52 Week Low US$2.07 Beta 0.91 1 Month Change 13.18% 3 Month Change -10.15% 1 Year Change -35.54% 3 Year Change 0% 5 Year Change -19.11% Change since IPO -94.01%
Recent News & Updates
New minor risk - Share price stability Jan 21
CEO, Chairman & Co-Chair of CBAB recently bought US$96k worth of stock Jan 16
Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 40%? Dec 19
Anixa Biosciences, Inc Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial Nov 19
Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the Society for Immunotherapy of Cancer Annual Meeting Nov 09
Now 20% undervalued Nov 04 See more updates
New minor risk - Share price stability Jan 21
CEO, Chairman & Co-Chair of CBAB recently bought US$96k worth of stock Jan 16
Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 40%? Dec 19
Anixa Biosciences, Inc Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial Nov 19
Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the Society for Immunotherapy of Cancer Annual Meeting Nov 09
Now 20% undervalued Nov 04
Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial Oct 15
Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development Oct 07
Anixa Biosciences, Inc. Announces Submission of Protocol Amendment for CAR-T Trial Oct 01
New minor risk - Share price stability Sep 25
We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate Sep 12
Lead Independent Director recently bought US$84k worth of stock Aug 02
Anixa Biosciences Announces Japanese Patent on Breast Cancer Vaccine Technology Jul 17 Anixa Biosciences, Inc. (NasdaqCM:ANIX) announces an Equity Buyback for $5 million worth of its shares. Jul 16
Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial Jun 25
CEO, Chairman & Co-Chair of CBAB recently bought US$60k worth of stock Jun 10
New major risk - Revenue and earnings growth Jun 06
Anixa Biosciences, Inc. Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial May 24
We're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash Wisely May 23
Anixa Biosciences Welcomes Sanjay Juneja to Its Cancer Business Advisory Board Apr 19
CEO, Chairman & Co-Chair of CBAB recently bought US$97k worth of stock Mar 17
New minor risk - Market cap size Mar 13
New major risk - Revenue and earnings growth Feb 14
Anixa Biosciences, Inc., Annual General Meeting, Mar 21, 2024 Feb 09
New minor risk - Share price stability Feb 02
Anixa Biosciences, Inc. Announces Japanese Patent on Ovarian Cancer Vaccine Technology Jan 23
We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Jan 19
Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine Dec 07
Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology Nov 29
Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology Nov 28
Anixa Biosciences, Inc. Appoints Mark A. Goldberg, Md, to Its Cancer Business Advisory Board Oct 24
Anixa Biosciences, Inc. Completes Treatment of First Patient Cohort in Ovarian Cancer CAR-T Clinical Trial Oct 14
We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth Oct 06
Anixa Biosciences, Inc. Establishes Cancer Business Advisory Board Sep 20
Anixa Biosciences, Inc. Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial Aug 08
Lead Independent Director exercised options to buy US$119k worth of stock. Aug 02
Press Release: Anixa Biosciences Announces Notice of Allowance of Additional Patent on Ovarian Cancer Vaccine Technology Jul 28
Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation? Apr 27
Now 38% undervalued after recent price drop Apr 17
Price target increased by 11% to US$10.50 Mar 23
Anixa Biosciences, Inc., Annual General Meeting, Mar 09, 2023 Jan 28
Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%? Jan 13
Forecast to breakeven in 2024 Jan 06
Forecast to breakeven in 2024 Dec 27
Anixa Biosciences Announces Maximum Tolerated Dose Reached in Trial of Preventative Breast Cancer Vaccine Dec 10
Insufficient new directors Nov 16
Insufficient new directors Nov 02
Anixa Biosciences Inc. Announces Commencement of Phase 1B Trial of Its Breast Cancer Vaccine At Cleveland Clinic Oct 27
Lead Independent Director exercised options to buy US$197k worth of stock. Oct 01
We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow Sep 26
Chairman & CEO exercised options and sold US$937k worth of stock Sep 17
Anixa Biosciences Announces Treatment of First Patient in Its Ovarian Cancer Car-T Clinical Trial Aug 16
Anixa adds 11% after dosing initiation in CAR-T ovarian cancer trial Aug 15
Anixa to get additional US patent linked to breast cancer vaccine technology Jul 21
Lead Independent Director exercised options to buy US$144k worth of stock. Jun 29
Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans Jun 13
Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times May 11
Price target increased to US$11.00 Apr 27
Anixa Biosciences, Inc. Announces Management Changes Apr 16
Anixa Biosciences, Inc. Announces the Initiation of its Ovarian Cancer CAR-T Phase 1 Trial at Moffitt Cancer Center Mar 31
We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow Feb 24
Anixa Biosciences, Inc., Annual General Meeting, Mar 10, 2022 Jan 30
Anixa Biosciences, Inc., Annual General Meeting, Mar 10, 2022 Jan 29
Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Jan 26
Anixa Biosciences and MolGenie Announce Early Potency Analysis of SARS-CoV-2 Protease Inhibitor Jan 25
Chairman recently bought US$60k worth of stock Jan 08
Anixa Biosciences and Molgenie Announce That Their Covid-19 Compounds Are Expected to Be Effective Against the Omicron Variant Dec 09
Lead Independent Director recently bought US$87k worth of stock Nov 02
Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth Oct 28
Our First Look At Anixa Biosciences Sep 23
Anixa Biosciences' Covid-19 Compounds Expected to Be Effective Against the Delta Variant Aug 26
Anixa Biosciences, Inc. Announces Issuance of U.S. Patent for Ovarian Cancer Vaccine Technology Aug 20
Board Member recently bought US$82k worth of stock Jul 28
Lead Independent Director recently bought US$87k worth of stock Jul 16
Consensus forecasts updated Jun 20
Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation Jun 12
Independent Director has left the company May 27
Independent Director has left the company May 27
Anixa Biosciences, Inc Receives Additional Information Request from US FDA for CAR-T IND Application May 21
OntoChem assigns Anixa covid-19 drug discovery project to MolGenie May 07
Lead Independent Director recently bought US$218k worth of stock Mar 27
Price target increased to US$9.00 Mar 24
Earnings miss expectations Mar 14
New 90-day high: US$5.84 Mar 13
Anixa Biosciences, Inc. Announces European Patent Issued for Its CAR-T Cancer Therapy Mar 05
Anixa Biosciences, Inc. Begins Animal Testing of Covid-19 Therapeutic Candidates Feb 17
New 90-day high: US$4.67 Feb 04
New 90-day high: US$4.38 Jan 15
Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans Jan 13
New 90-day high: US$3.19 Dec 31
Anixa Biosciences and Cleveland Clinic Announce FDA Clearance to Initiate Clinical Trial of Breast Cancer Vaccine Dec 23
Anixa Biosciences, Inc. Covid-19 Therapy Demonstrates Comparable Potency to Remdesivir in Pre-Clinical Testing Dec 15
New 90-day high: US$3.03 Dec 09
Anixa Biosciences, Inc. Announces Licensing Agreement with Cleveland Clinic for Ovarian Cancer Vaccine Technology Dec 02
Anixa Biosciences, Cleveland Clinic in ovarian cancer vaccine pact Dec 01
Lead Independent Director recently bought US$83k worth of stock Sep 15 Shareholder Returns ANIX US Biotechs US Market 7D 13.2% 4.7% 3.0% 1Y -35.5% -3.1% 25.2%
See full shareholder returns
Return vs Industry: ANIX underperformed the US Biotechs industry which returned -4.1% over the past year.
Return vs Market: ANIX underperformed the US Market which returned 25% over the past year.
Price Volatility Is ANIX's price volatile compared to industry and market? ANIX volatility ANIX Average Weekly Movement 11.9% Biotechs Industry Average Movement 11.4% Market Average Movement 6.5% 10% most volatile stocks in US Market 18.8% 10% least volatile stocks in US Market 3.3%
Stable Share Price: ANIX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ANIX's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs include the development of a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company’s vaccine programs include the development of a vaccine against breast cancer, initially focused on triple negative breast cancer (TNBC), the most lethal form of breast cancer; and the development of a vaccine against ovarian cancer, as well as a vaccine discovery program to develop additional cancer vaccines to address intractable cancers, including high incidence malignancies in lung, colon, and prostate.
Show more Anixa Biosciences, Inc. Fundamentals Summary How do Anixa Biosciences's earnings and revenue compare to its market cap? ANIX fundamental statistics Market cap US$95.78m Earnings (TTM ) -US$12.55m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ANIX income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$12.55m Earnings -US$12.55m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/23 05:43 End of Day Share Price 2025/01/23 00:00 Earnings 2024/10/31 Annual Earnings 2024/10/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Anixa Biosciences, Inc. is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Andrew D'Silva B. Riley Securities, Inc. Jason Kolbert D. Boral Capital LLC. Yi Chen H.C. Wainwright & Co.
Show 1 more analysts 
